Gwinner,
Just curious ...... what's special about "this week" ? Unless I have missed something I'm not sure there are any expectations for communications presently.
Do shareholders need an update ??? .... YES .... any communication is a plus and certainly anything with DEFINITIVE timelines.
Avian flu ... unfortunately last PR left door open on "WHEN" so who knows if started, inprogress, done, when ?
Coccidiosis ...... my preference is full bore get it done by end of month for license ...... but my opinion is new avian fly vertical may have shifted the timeline with the potential of more animal pharmas asking questions and potentially desiring to get into the mix. My guess is at least 2 very interested. A third possibly ... and maybe more. ZIVO has had at least 2 collaborations with 2 different major animal pharmas. One is definitely Zoetis (bovine mastitis). I do not know who did their own test on coccidiosis but given how that test was done, I'm guessing it is a pharma with a comprehensive coccidiosis disease mgmt program which I don't think is Zoetis. The timeline of news would seem it indicate another pharma jumped in on coccidiosis. Dunno who that one is either. And who knows who else is interested by avian flu results.
It would seem the largest number of industry eyes would be on ZIVO right now ...... a great time to entertain buyout offers. INFLAMMATION,INFLAMMATION,INFLAMMATION. GUT HEALTH ... guess what .... rooted in INFLAMMATION. There is no doubt in my mind the algae and it's derivatives regulate inflammation in the body. Therefore the verticals are many.
IMO, ideally the algae and its variants fit the best with a pharma with human and animal divisions ..... ya get both applications in one shot. That narrows the field of potential candidates but offers the most bang for the buck for a pharma with all the vertical options ... plus they can get into both human and animal ingredients markets as well. WIN WIN in my book for them. And ZIVO already done a large part of the legwork and filed patents. $500 million for both human and animal vertical options is cheap in my book. ($100/share fully diluted) The pharma can hit the ground running.
So it is difficult to ascertain WHERE exactly things stand. Who is involved. At what stage anything sits .... other than coccidiosis is at license stage.
Trading is thin and stagnant stock movement for now ..... so no indications there. No major selling although appears someone trying to offload several thousand shares recently.
The annual 10K is due shortly .... and of course .... is a PERFECT opportunity for Payne to provide more of a broad update across the board and VISION INTO THE FUTURE. But ZIVO has been relatively poor with those kinds of things. In the Dahl era that was mainly offered at annual shareholder meetings. But another year of tests and losses for shareholders.
Odds on update ? Personally I wasn't expecting anything this week and I am assuming delays due to more eyes on it and "1H" offered in Microcap conference update. JMHO.
Amigo Mike
Market Data 
Markets 
AI
